China
Africa
Explore chapters and articles related to this topic
Anxiety
Published in Carolyn Torkelson, Catherine Marienau, Beyond Menopause, 2023
Carolyn Torkelson, Catherine Marienau
CBD has been gaining in popularity for many conditions, and early research is promising regarding its ability to help relieve anxiety. CBD can be derived from both hemp and marijuana plants. Hemp has been cultivated for many years and used to make clothing and various fiber products. However, because hemp and marijuana both come from cannabis plants, there is much confusion about the difference between the two compounds. So, what are the facts? The cannabis plant has several varieties, which contain different compounds called cannabinoids. CBD is a cannabinoid, as is tetrahydrocannabinol (THC).THC is a psychoactive compound—it is the stuff that gets you high.CBD products derived from hemp are a particular variety of the cannabis plant. They contain less than 0.3% THC and do not have any psychoactive effects. They are legal federally, but still illegal under some state laws.Marijuana is derived from varieties of the cannabis plant that contain much higher and varying amounts of THC. Marijuana is illegal federally, but legal under some state laws.
Persistent Physical Symptoms
Published in James Matheson, John Patterson, Laura Neilson, Tackling Causes and Consequences of Health Inequalities, 2020
Lastly, in relation to biological considerations, we must remember drugs, prescribed or otherwise, as either causative or maintaining factors in PPS. Through direct harm, side effects or withdrawal syndromes many medications can worsen symptoms. Looking at timings of medication prescription, or dose changes, may help to understand symptom progression. Equally, non-prescribed drugs may worsen or relieve symptoms and must be enquired about. Cannabis in particular is often used by people for pain relief.
Cannabis
Published in Ilana B. Crome, Richard Williams, Roger Bloor, Xenofon Sgouros, Substance Misuse and Young People, 2019
The strong association of cannabis and tobacco use poses significant risks to people of all ages, but especially the adolescent population, which may be more vulnerable to the respiratory effects of smoking. Studies suggest that cannabis, which is inhaled more deeply by smokers, can also lead to respiratory symptoms, such as increased cough and sputum production, damage to the mucosa, and that it affects immunoregulation, such that smokers are predisposed to lower respiratory tract infections (Gates et al., 2014). Further research, which controls for tobacco use and environmental exposure to other toxins, is needed to clarify the extent to which these effects cause obstructive airways disease, result in emphysema, or contribute to the development of lung cancer.
A primer on sleeping, dreaming, and psychoactive agents
Published in Journal of Social Work Practice in the Addictions, 2023
The endocannabinoid system is a complicated biological system involved in regulating movement, mood, memory, appetite, fertility, pain, and physiological homeostasis. It consists of cannabinoid receptors and cannabinoid receptor proteins that are active throughout both the central and peripheral nervous systems. Two endogenous molecules that activate the endocannabinoid system have been found. The first, 2-arachidonoyl glycerol (2-AG), occurs in peripheral tissues, while anandamide (Sanskrit for ‘supreme joy’) is a neurotransmitter. The psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), mimics the actions of anandamide, whereas the main therapeutic component of cannabis, cannabidiol (CBD), mimics 2-AG (Mechoulan & Parker, 2013). Data from the past 20 years indicates that the endocannabinoid system plays a role in modulating the human sleep-wake cycle and can play a part in the decrease in sleep disturbance or insomnia through the restoration of sleeping and dreaming through the regulation of how this occurs is not yet fully understood (Kesner & Lovinger, 2020; Prospéro-García et al., 2016).
Antibacterial, antioxidant, and haemolytic potential of silver nanoparticles biosynthesized using roots extract of Cannabis sativa plant
Published in Artificial Cells, Nanomedicine, and Biotechnology, 2022
Suman Suman, Lacy Loveleen, Meena Bhandari, Asad Syed, Ali H. Bahkali, Romila Manchanda, Surendra Nimesh
In this investigation, the ethanolic root extract of Cannabis sativa, commonly known as, Marijuana or Hemp, has been used for the synthesis of silver nanoparticles. Cannabisbelongs to the family Cannabaceae, and is a cosmopolitan herbaceous plant, originating from Central Asia. For millennia, Cannabis has been used for the treatment of pain, insomnia, spasm, asthma, depression and anorexia. Cannabinoids, terpenoids, sterols and flavonoids are some of the common secondary metabolites of the plant that have substantially contributed towards its therapeutic potential and for the biosynthesis of AgNPs [18]. Herein, the AgNPs synthesis has been performed through optimization of reaction parameters mainly concentration of silver nitrate salt (AgNO3), temperature, volume of root extract, and pH, of the reaction [19]. Further, the antibacterial property of the extract was checked against Gram-negative (Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae) and Gram-positive (Staphylococcus aureus) bacterial species. The study also highlights the antioxidant, and reduced haemolytic properties of AgNPs against the HEK 293 cells and human RBCs.
Clinical documentation of patient-reported medical cannabis use in primary care: Toward scalable extraction using natural language processing methods
Published in Substance Abuse, 2022
David S. Carrell, David J. Cronkite, Mary Shea, Malia Oliver, Casey Luce, Theresa E. Matson, Jennifer F. Bobb, Clarissa Hsu, Ingrid A. Binswanger, Kendall C. Browne, Andrew J. Saxon, Jennifer McCormack, Eve Jelstrom, Udi E. Ghitza, Cynthia I. Campbell, Katharine A. Bradley, Gwen T. Lapham
Medical cannabis use is legal in 37 U.S. states. Eighteen states plus the District of Columbia have legalized adult recreational use and another 13 states have decriminalized cannabis use. The National Academy of Sciences has stressed the need for clinical epidemiological research to investigate the safety and effectiveness of medical cannabis use for a variety of health conditions.1 To enable large-scale observational studies and pragmatic trials to address these knowledge gaps, automated algorithms using electronic health records (EHR) data to define phenotypes of medical cannabis use are needed. Many people may use cannabis to manage medical or behavioral health symptoms, and in some cases to replace prescribed medications or other treatments with proven efficacy—potentially without adequately understanding the tradeoffs.1 Understanding how often that occurs by distinguishing medical from non-medical cannabis use in large patient populations is important for facilitating research to address these knowledge gaps.